| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877792 | CHEMO RESEARCH SL | Compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Feb, 2028
(4 years from now) | |
| US7893097 | CHEMO RESEARCH SL | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Feb, 2028
(4 years from now) | |
| US8658678 | CHEMO RESEARCH SL | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Jun, 2028
(4 years from now) | |
| US10238634 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
| US8946276 | CHEMO RESEARCH SL | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
Jun, 2032
(8 years from now) | |
| US9198858 | CHEMO RESEARCH SL | Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
| US10596155 | CHEMO RESEARCH SL | Aqueous-based metronidazole gel formulations |
Jun, 2032
(8 years from now) | |
Nuvessa is owned by Chemo Research Sl.
Nuvessa contains Metronidazole.
Nuvessa has a total of 7 drug patents out of which 0 drug patents have expired.
Nuvessa was authorised for market use on 24 March, 2014.
Nuvessa is available in gel;vaginal dosage forms.
Nuvessa can be used as treatment of bacterial vaginosis, treatment of bacterial vaginosis with metronidazole gel.
The generics of Nuvessa are possible to be released after 28 June, 2032.
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 24 March, 2014
Treatment: Treatment of bacterial vaginosis; Treatment of bacterial vaginosis with metronidazole gel
Dosage: GEL;VAGINAL
NUVESSA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic